Compare Quest Diagnostics Inc (DGX) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Gigacloud Technology Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Gigacloud Technology Inc trades at $57.26 (market cap $2.02B). The key difference: Quest Diagnostics Inc is far larger — about 12.6× Gigacloud Technology Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Gigacloud Technology Inc for 21 Days on average.
| DGX | GCT | |
|---|---|---|
Market Cap | $25.48B | $2.02B |
Volume | 941,866 | 1,020,985 |
Sector | Health | Technology |
52-Week High | $247.45 | $56.42 |
52-Week Low | $173.49 | $25.46 |
Typical Hold Time | 56 Days | 21 Days |
Enterprise Value | $31.23B | $2.14B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
GCT trades at $57.26, up 2.32% today, with a bullish technical outlook and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock shows robust profitability with a 10.65% net income margin and 32.34% ROE, supported by positive cash flow from operations of $190.66 million in 2025. Recent news highlights institutional interest and expansion into European markets.
The outlook is positive with revenue growth to $1.5 billion projected for 2026 and a consensus analyst price target of $32.50, though risks include insider selling and competitive pressures in the consumer discretionary sector. The stock's current price near resistance at $58 suggests potential for volatility amid overbought short-term conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
